TITLE

Health Canada proposes new regulatory regime for drugs

AUTHOR(S)
Kondro, Wayne
PUB. DATE
April 2007
SOURCE
CMAJ: Canadian Medical Association Journal;4/24/2007, Vol. 176 Issue 9, p1261
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that Health Canada is proposing a new regulatory regime for pharmaceuticals and biologics. The proposition was to support its move to lower the threshold for initial market authorization licenses in exchange for additional safety and efficacy studies as the condition for selling drug. The regulatory regime incorporates the notion of post-market surveillance into Health Canada. Nevertheless, the changes that the proposed regime offers are still being reviewed.
ACCESSION #
25007855

 

Related Articles

  • Plain language drug labels:. Cross, Catherine // CMAJ: Canadian Medical Association Journal;9/17/2013, Vol. 185 Issue 13, pE626 

    The article reports on a 75-day stakeholder consulting period being conducted by Health Canada before implementing rules aimed at ensuring that drug labels are written in plain, understandable language and preventing confusion over drug names, as of September 2013.

  • Pan-Canadian opioid strategy to be released amid brouhaha. Miller, Adam // CMAJ: Canadian Medical Association Journal;2/5/2013, Vol. 185 Issue 2, pE89 

    The article offers information on the issues related to opioids strategy in Canada. As mentioned, Health Canada, department of the government of Canada with responsibility for national public health, has provided financial support for the development of a pan-Canadian strategy to combat...

  • Waits for Access to New Biological and Pharmaceutical Medicines: Evidence of Government Failure. Skinner, Brett J.; Rovere, Mark // Fraser Forum;Jun2007, p7 

    The article presents the evidences of the delayed approval of drugs by the federal government in Canada. According to a study, provincial officials wait longer to make such drugs eligible despite being declared safe and effective by Health Canada due to differences involving the kind of drugs...

  • Recovery and Continuity Session #1.  // Canadian Journal of Public Health;Mar/Apr2004, Vol. 95 Issue 2, p14 

    Presents a recovery and continuity session on regulated process recovery in public health disasters at the Canadian Conference on Counter-Terrorism and Public Health held in Toronto, Ontario. Need to review the Food and Drug Act to bring into today's context of risk and threat with respect to...

  • Pharmacogenomics guidance from Health Canada.  // WHO Drug Information;2007, Vol. 21 Issue 3, p245 

    The article reports that Health Canada has released the final version of the regulatory guidance Submission of Pharmacogenomic Information. It cited that the document provides guidance to sponsors on how and when to submit pharmacogenomic information to the company. It cited that it also...

  • In the Public Interest? Robertson, Elizabeth // LawNow;Nov/Dec2008, Vol. 33 Issue 2, p21 

    The article focuses on the changes in federal legislation related to drug advertising in Canada. It mentions that the new federal regulations allow manufacturers of natural health products and many over-the-counter drugs to advertise that their products will prevent diseases in relation to a...

  • Ottawa passes drug safety law. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;8/5/2014, Vol. 186 Issue 11, p818 

    The article reports that Ottawa's House of Commons approved the Bill C-17, a drug safety law which amends the Food and Drugs Act. Topics discussed include the law to give authority to the minister of health to order a drug off the market if surveillance data showed a serious risk, authority for...

  • Patients Waiting Too Long for Government Permission to Use New Drugs in Canada. Skinner, Brett J. // Fraser Forum;Jun2007, p4 

    The article focuses on the delayed approval of drugs by the federal government in Canada. A study revealed that such delay took 491 days on average in 2005, which is believed to cause the patients to lose potential health benefits as they wait until such drugs are approved safe and effective to...

  • POST-MARKET DRUG EVALUATION RESEARCH TRAINING CAPACITY IN CANADA: AN ENVIRONMENTAL SCAN OF CANADIAN EDUCATIONAL INSTITUTIONS. Wiens, Matthew O.; Soon, Judith A.; MacLeod, Stuart M.; Sharma, Sunaina; Patel, Anik // Journal of Population Therapeutics & Clinical Pharmacology;2014, Vol. 21 Issue 3, pe370 

    Background Ongoing efforts by Health Canada intended to modernize the legislation and regulation of pharmaceuticals will help improve the safety and effectiveness of drug products. It will be imperative to ensure that comprehensive and specialized training sites are available to train...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics